Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wei-Xiang, Wang, Qiong, Jiang, Yan-Ling, Sun, Yuan-Jue, Tang, Li-na, He, Ai-na, Min, Da-liu, Lin, Feng, Shen, Zan, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568141/
https://www.ncbi.nlm.nih.gov/pubmed/23409011
http://dx.doi.org/10.1371/journal.pone.0055637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568141/
https://www.ncbi.nlm.nih.gov/pubmed/23409011
http://dx.doi.org/10.1371/journal.pone.0055637

Ejemplares similares